Article

Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment.

Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0676, USA.
BMC Nephrology (Impact Factor: 1.52). 02/2006; 7:6. DOI: 10.1186/1471-2369-7-6
Source: PubMed

ABSTRACT A reduction in the number of podocytes and podocyte density has been documented in the kidneys of patients with diabetes mellitus. Additional studies have shown that podocyte injury and loss occurs in both diabetic animals and humans. However, most studies in animals have examined relatively long-term changes in podocyte number and density and have not examined effects early after initiation of diabetes. We hypothesized that streptozotocin diabetes in rats and mice would result in an early reduction in podocyte density and that this reduction would be prevented by antioxidants.
The number of podocytes per glomerular section and the podocyte density in glomeruli from rats and mice with streptozotocin (STZ)-diabetes mellitus was determined at several time points based on detection of the glomerular podocyte specific antigens, WT-1 and GLEPP1. The effect of insulin administration or treatment with the antioxidant, alpha-lipoic acid, on podocyte number was assessed.
Experimental diabetes resulted in a rapid decline in apparent podocyte number and podocyte density. A significant reduction in podocytes/glomerular cross-section was found in STZ diabetes in rats at 2 weeks (14%), 6 weeks (18%) and 8 weeks (34%) following STZ injection. Similar declines in apparent podocyte number were found in STZ diabetes in C57BL/6 mice at 2 weeks, but not at 3 days after injection. Treatment with alpha-lipoic acid substantially prevented podocyte loss in diabetic rats but treatment with insulin had only a modest effect.
STZ diabetes results in reduction in apparent podocyte number and in podocyte density within 2 weeks after onset of hyperglycemia. Prevention of these effects with antioxidant therapy suggests that this early reduction in podocyte density is due in part to increased levels of reactive oxygen species as well as hyperglycemia.

0 Bookmarks
 · 
128 Views
  • Source
    01/2010;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To observe the effects of Alpha-lipoic acid (ALA) on oxidative stress (OS) in vivo and urinary podocalyxin (PCX, the glomerular podocyte marker protein) excretion in type 2 diabetics and explore its possible protective mechanisms on glomerular podocytes. Methods 36 type 2 diabetics were recruited as observation group and treated with ALA on the basis of initial therapy for six months, and 30 healthy subjects were selected as control group. FBG, HbA1c, serum glutathione peroxidase (SGSH-Px), superoxide dismutase (SSOD) activity, urinary malondialdehyde (UMDA), 8-hydroxy-deoxyguanosine (U8-OHdG), albumin (UALB), creatinine (UCr) and urinary PCX (UPCX) were determined at baseline and after six months’ observation. Results Compared with the control group, the ratios of UMDA/UCr (UMCR), U8-OHdG /UCr (U8CR), UALB/UCr (UACR) and UPCX/UCr (UPCR) increased markedly, SGSH-Px and SSOD decreased significantly in the diabetics (P < 0.01); After sixth month treatment, the levels of UMCR, U8CR, UACR and UPCR reduced and SGSH-Px, SSOD increased markedly in the observation group (P < 0.05) with nosignificant changes in FBG and HbA1c. UPCR had positive correlation with UACR, UMCR and U8CR (r = 0.720, r = 0.661, r = 0.698, P < 0.01), and negative correlation with SGSH-Px and SSOD in the diabetics (r = -0.608, r = -0.559, P < 0.01). Conclusion ALA can provide some protection against glomerular podocyte injury in type 2 diabetics, which may be related partly to its effects in alleviating enhanced OS and strengthening antioxidant ability in vivo.
    Journal of Diabetes and its Complications 09/2014; · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hyperglycemia stimulates secretion of αVβ3 ligands from vascular cells including endothelial cells resulting in activation of the αVβ3 integrin. This study determined if blocking ligand occupancy of αVβ3 would inhibit the development of diabetic nephropathy. Ten diabetic pigs received an F(ab)2 fragment of an antibody directed against the extracellular domain of the β3 subunit and ten received a control IgG F(ab)2 for 18 weeks. Non-diabetic pigs excreted 115 ± 50 μg of protein/mg creatinine compared to control F(ab)2 treated diabetic animals (218± 57 μg/mg) whereas diabetic animals treated with the anti-β3 F(ab)2 excreted 119 ± 55 μg/mg (p<0.05). Mesangial volume/glomerular volume increased to 21 ± 2.4 in control treated diabetic animals compared to 14 ± 2.8% (p<0.01) in animals treated with active antibody. Diabetic animals treated with control F(ab)2 had significantly less glomerular podocin staining compared to nondiabetic animals and this decrease was attenuated by treatment with anti-β3 F(ab)2. Glomerular basement membrane thickness was increased in the control, F(ab)2 treated diabetic animals (212±14 nm) compared to nondiabetic animals (170 ± 8.8 nm) but it was unchanged (159.9 ± 16.4 nm) in animals receiving anti-β3 F(ab)2. Podocyte foot process width was greater in control, F(ab)2 treated, animals (502± 34 nm) compared to animals treated with the anti-β3 F(ab)2 (357±47 nm, p<0.05). Renal β3 tyrosine phosphorylation decreased from 13,934 ± 6437 to 6730 ± 1524 (p<0.01) scanning units in the anti-β3 treated group. We conclude that administration of an antibody that inhibits activation of the β3 subunit of αVβ3 that is induced by hyperglycemia attenuates proteinuria and early histologic changes of diabetic nephropathy suggesting that it may have utility in preventing the progression of this disease complication.
    Endocrinology 08/2014; · 4.72 Impact Factor

Full-text (2 Sources)

Download
23 Downloads
Available from
May 21, 2014